Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.57 |
| ▸ | GSK3B | P49841 | 16/20 | 0.57 |
| ▸ | WNT1 | P04628 | 15/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699525 | 0.84 | GSK3B (0.50) | DYRK1AGSK3BWNT1EP300ABL1 | |
| SCHEMBL19699545 | 0.80 | EP300 (0.46) | DYRK1AGSK3BWNT1EP300BRD4 | |
| SCHEMBL24358102 | 0.79 | DYRK1A (0.48) | DYRK1AGSK3BWNT1EP300BRD4 | |
| SCHEMBL24932350 | 0.78 | EGFR (0.61) | GSK3B | |
| SCHEMBL19699521 | 0.78 | DYRK1A (0.48) | DYRK1AGSK3BWNT1 | |
| SCHEMBL19706568 | 0.78 | BRD4 (0.44) | DYRK1AGSK3BWNT1EP300BRD4 | |
| SCHEMBL28508343 | 0.78 | FYN (0.49) | DYRK1AGSK3BWNT1BRD4CREBBP | |
| SCHEMBL19699587 | 0.78 | PIK3C3 (0.43) | GSK3BEP300ABL1 | |
| SCHEMBL21285738 | 0.77 | WNT1 (0.74) | DYRK1AGSK3BWNT1EP300 | |
| SCHEMBL19699600 | 0.77 | MKNK1 (0.55) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 3048/4885GSK3B 2322/4885WNT1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.